1244.Hk
The company operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.
Business. The company operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.
The company's capital structure is characterized by a market capitalization of 911.36 million CNY and a price-to-book ratio of 1.53, indicating a moderate premium over its book value. The company's liquidity position is assessed as medium, with a current ratio of 1.45, suggesting it can cover its short-term liabilities but with limited buffer. The debt-to-equity ratio of 0.26 indicates a relatively conservative leverage profile, with long-term debt amounting to 152.78 million CNY.
Profitability metrics reveal a challenging financial position, with a negative return on equity of -29.75% and a negative return on assets of -18.96%. The company reported a net loss of 177.53 million CNY and an operating loss of 179.71 million CNY, indicating significant operational inefficiencies. Gross profit of 327.91 million CNY was insufficient to offset operating expenses, resulting in a negative operating margin.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the ability to offset losses in one area with gains in another. The absence of segment or geographic breakdown in the financial data suggests a need for further transparency.
The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent period. The operating and net losses suggest a lack of profitability, and without a clear path to positive earnings, future growth is speculative. The company's outlook for the current fiscal year is not provided, but the negative operating performance raises concerns about its ability to achieve revenue or profit growth in the near term.
Risk factors include a negative net cash position after subtracting total debt, which indicates potential liquidity constraints. The company's dilution risk is assessed as low, with no significant dilution events reported in the recent financial data. However, the negative net income and operating cash flow could necessitate future equity or debt financing, which may lead to dilution.
Recent events include the publication of the latest financial data, which shows a continued net loss and negative operating income. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or operational performance. The absence of recent events or disclosures suggests a lack of transparency and may limit investor confidence.
- The company is operating at a net loss, with a negative return on equity and return on assets.
- The company's liquidity position is moderate, with a current ratio of 1.45 and a debt-to-equity ratio of 0.26.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company's growth trajectory is uncertain, with no disclosed revenue growth and negative operating performance.
- The company's risk profile includes a negative net cash position and potential liquidity constraints.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 1244.HK Market data — financials · 2026-05-26